TRVI Quote, Financials, Valuation and Earnings

Checkpoint Therapeutics(DELISTED) has a net margin of -- compared to Trevi Therapeutics's net margin of --. Trevi Therapeutics's return on equity of -- beat Checkpoint Therapeutics(DELISTED)'s return on equity of --.

Trevi Therapeutics has a consensus price target of $21.22, signalling upside risk potential of 239.56%. On the other hand Checkpoint Therapeutics(DELISTED) has an analysts' consensus of -- which suggests that it could grow by 4.46%. Given that Trevi Therapeutics has higher upside potential than Checkpoint Therapeutics(DELISTED), analysts believe Trevi Therapeutics is more attractive than Checkpoint Therapeutics(DELISTED).

Trevi Therapeutics has a beta of 0.591, which suggesting that the stock is 40.892% less volatile than S&P 500. In comparison Checkpoint Therapeutics(DELISTED) has a beta of 1.128, suggesting its more volatile than the S&P 500 by 12.767%.

Trevi Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Checkpoint Therapeutics(DELISTED) offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trevi Therapeutics pays -- of its earnings as a dividend. Checkpoint Therapeutics(DELISTED) pays out -- of its earnings as a dividend.

Trevi Therapeutics quarterly revenues are --, which are smaller than Checkpoint Therapeutics(DELISTED) quarterly revenues of --. Trevi Therapeutics's net income of -$10.3M is higher than Checkpoint Therapeutics(DELISTED)'s net income of -$11.2M. Notably, Trevi Therapeutics's price-to-earnings ratio is -- while Checkpoint Therapeutics(DELISTED)'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trevi Therapeutics is -- versus -- for Checkpoint Therapeutics(DELISTED). Usually stocks with elevated PS ratios are considered overvalued.

Collegium Pharmaceutical has a net margin of -- compared to Trevi Therapeutics's net margin of 1.36%. Trevi Therapeutics's return on equity of -- beat Collegium Pharmaceutical's return on equity of 19.31%.

Trevi Therapeutics has a consensus price target of $21.22, signalling upside risk potential of 239.56%. On the other hand Collegium Pharmaceutical has an analysts' consensus of $41.25 which suggests that it could grow by 38.94%. Given that Trevi Therapeutics has higher upside potential than Collegium Pharmaceutical, analysts believe Trevi Therapeutics is more attractive than Collegium Pharmaceutical.

Trevi Therapeutics has a beta of 0.591, which suggesting that the stock is 40.892% less volatile than S&P 500. In comparison Collegium Pharmaceutical has a beta of 0.635, suggesting its less volatile than the S&P 500 by 36.534%.

Trevi Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Collegium Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trevi Therapeutics pays -- of its earnings as a dividend. Collegium Pharmaceutical pays out -- of its earnings as a dividend.

Trevi Therapeutics quarterly revenues are --, which are smaller than Collegium Pharmaceutical quarterly revenues of $177.8M. Trevi Therapeutics's net income of -$10.3M is lower than Collegium Pharmaceutical's net income of $2.4M. Notably, Trevi Therapeutics's price-to-earnings ratio is -- while Collegium Pharmaceutical's PE ratio is 24.34x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trevi Therapeutics is -- versus 1.72x for Collegium Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Trevi Therapeutics's net margin of -49.65%. Trevi Therapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Trevi Therapeutics has a consensus price target of $21.22, signalling upside risk potential of 239.56%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 41.9%. Given that Trevi Therapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Trevi Therapeutics is more attractive than NovaBay Pharmaceuticals.

Trevi Therapeutics has a beta of 0.591, which suggesting that the stock is 40.892% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.305%.

Trevi Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trevi Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Trevi Therapeutics quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Trevi Therapeutics's net income of -$10.3M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Trevi Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trevi Therapeutics is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -- compared to Trevi Therapeutics's net margin of --. Trevi Therapeutics's return on equity of -- beat Theriva Biologics's return on equity of --.

Trevi Therapeutics has a consensus price target of $21.22, signalling upside risk potential of 239.56%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1220.76%. Given that Theriva Biologics has higher upside potential than Trevi Therapeutics, analysts believe Theriva Biologics is more attractive than Trevi Therapeutics.

Trevi Therapeutics has a beta of 0.591, which suggesting that the stock is 40.892% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.848, suggesting its less volatile than the S&P 500 by 15.165%.

Trevi Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trevi Therapeutics pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Trevi Therapeutics quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Trevi Therapeutics's net income of -$10.3M is lower than Theriva Biologics's net income of -$4.3M. Notably, Trevi Therapeutics's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trevi Therapeutics is -- versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.